We value your privacy
This site uses cookies to improve your browsing experience, analyze site traffic, and show personalized content.
| No holders yet. | ||||||||||
SAB Biotherapeutics developed SAB-163, the world's first fully human polyclonal antibody therapy designed to directly neutralize life-threatening Hantavirus infections. Powered by their unique DiversitAb™ platform and backed by the US Department of Defense, the company leads the global effort in providing rapid, life-saving medical countermeasures for Hantavirus outbreaks.